needed effects
emtricitabine
tenofovir alafenamide
unwanted side effects
medical attention
following side effects
taking emtricitabine
tenofovir alafenamide
check
doctor
emtricitabine
tenofovir alafenamide
side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
clinical studies
antiretroviral therapy-naive patients
rilpivirine in combination with emtricitabine-tenofovir disoproxil fumarate
df
common side effects
depression/depressive disorders
nausea
dizziness
abnormal dreams
headache
diarrhea
insomnia
treatment
side effects
severity
patients
taking rilpivirine in combination with emtricitabine-tenofovir df
common side effects
discontinuation
psychiatric disorders
virologically-suppressed patients
df
common side effects
fatigue
diarrhea
nausea
insomnia
manufacturer product information for emtricitabine
rilpivirine
tenofovir df
increased alt
grade
grade
grade
grade
ast
grade
grade
grade
grade
total bilirubin
grade
grade
grade
emtricitabine-tenofovir df
rilpivirine
severe acute exacerbations of hepatitis b
patients
hbv
hiv
discontinuation of emtricitabine
tenofovir df
liver failure
liver decompensation in some emtricitabine-treated patients
incidence of hepatic enzyme elevation
patients
receiving rilpivirine
hepatitis b
c
patients without coinfection
lactic acidosis
steatosis
including
fatal cases
use of nucleoside analogs
hepatic steatosis
hepatitis
postmarketing experience with tenofovir df
emtricitabine-tenofovir df
rilpivirine
increased alt
ast
increased total bilirubinemtricitabine
tenofovir df
frequency
severe hepatomegaly with steatosis
severe acute exacerbations of hepatitis bemtricitabine
elevated serum ast
elevated serum alt
hyperbilirubinemia-frequency
liver failure
liver decompensationrilpivirine
increased transaminases
ast
alt
cholecystitis
cholelithiasis
bilirubin-frequency
hepatic enzyme elevation
hepatotoxicity
drug-induced acute allergic hepatitistenofovir df
increased transaminases
ast
alt
hepatic steatosis
hepatitis-frequency
lactic acidosis/severe hepatomegaly with steatosis-postmarketing reports
elevated liver enzymes
ast
alt
ggt
emtricitabine-tenofovir df
rilpivirine
total cholesterol
fasted low-density lipoprotein
ldl
cholesterol
triglycerides
hypophosphatemiaemtricitabine
tenofovir alafenamide
frequency
increased total cholesterol
ldl cholesterol
high-density lipoprotein
hdl
cholesterol
triglyceridesemtricitabine
tenofovir df
frequency
increased alkaline phosphatase
serum glucose
lactic acidosisemtricitabine
hyperglycemia
hypertriglyceridemiarilpivirine
total cholesterol
fasted ldl cholesterol-common
decreased appetite
fasted triglyceridestenofovir df
hypophosphatemia-uncommon
hypokalemia-rare
lactic acidosisantiretroviral therapy
frequency
redistribution/accumulation of body fat
including
central obesity
dorsocervical fat enlargement
peripheral wasting
facial wasting
breast enlargement
cushingoid appearance
increased blood lipid levels
glucose levels
total cholesterol
grade
grade
grade
ldl cholesterol
grade
grade
grade
triglycerides
grade
grade
emtricitabine-tenofovir df
rilpivirine
clinical trials
following mean increases
antiretroviral therapy-naive patients
using emtricitabine
tenofovir alafenamide with elvitegravir
cobicistat for weeks
total cholesterol
mg/dl
ldl cholesterol by mg/dl
hdl cholesterol by mg/dl
triglycerides by mg/dl
increased alkaline phosphatase
units/l
serum glucose
mg/dl
emtricitabine
tenofovir df
lactic acidosis
steatosis
including
fatal cases
use of nucleoside analogs
hypokalemia
hypophosphatemia
result of proximal renal tubulopathy
lactic acidosis
hypokalemia
hypophosphatemia
postmarketing experience with tenofovir df
depression
insomnia
abnormal dreams
therapy-naive patients
emtricitabine
tenofovir df
anxiety
therapy-naive patients
emtricitabine
tenofovir df
phase trials through weeks
depressive disorders
causality
severity
patients
receiving rilpivirine
emtricitabine/rilpivirine/tenofovir df
insomniaemtricitabine-tenofovir df
rilpivirine
depression
depressive disorders
depressed mood
depression
dysphoria
major depression
altered mood
negative thoughts
suicide attempt
suicidal ideation
insomnia
abnormal dreamsemtricitabine
tenofovir df
depression
insomnia
abnormal dreams-common
anxietyemtricitabine
insomnia
abnormal dreamsrilpivirine
depressive disorders
anxiety
abnormal dreams
depression
sleep disorders
depressed mood
phase trials
patients
using rilpivirine with emtricitabine
tenofovir df
least grade
therapy-related rashes
rashes
grade
weeks of therapy
rash
therapy-naive patients
emtricitabine
tenofovir df
rash
postmarketing experience with tenofovir df
emtricitabine/rilpivirine/tenofovir df
postmarketing reports
severe skin
hypersensitivity reactions
including drug reaction with eosinophilia
systemic symptoms
dress
severe skin reactions with systemic symptoms
including rashes with fever
blisters
conjunctivitis
angioedema
elevated liver function tests
eosinophilia
emtricitabine-tenofovir df
rilpivirine
rashemtricitabine
tenofovir df
rash-frequency
lipodystrophyemtricitabine
vesiculobullous rash
pustular rash
maculopapular rash
rash
pruritus
urticaria
skin discoloration
palmar-plantar hyperpigmentation
postmarketing reports
angioedemarilpivirine
rash-postmarketing reports
severe skin
hypersensitivity reactions
including dress
tenofovir df
rash-postmarketing reports
angioedema
headache
dizziness
therapy-naive patients
emtricitabine
tenofovir df
paresthesia
peripheral neuropathy
including
peripheral neuritis
neuropathy
therapy-naive patients
emtricitabine
tenofovir df
emtricitabine-tenofovir df
rilpivirine
headache
dizzinessemtricitabine
tenofovir df
headache
paresthesia
peripheral neuropathy
including
peripheral neuritis
neuropathy
emtricitabine
headache-common
dizzinessrilpivirine
headache
somnolencetenofovir df
dizziness-common
headache
emtricitabine-tenofovir df
rilpivirine
increased creatinineemtricitabine
tenofovir alafenamide
frequency
increased serum creatinine
urine
protein-to-creatinine ratio
upcr
worsening
worsening renal functionrilpivirine
membranous glomerulonephritis
mesangioproliferative glomerulonephritis
nephrolithiasis-frequency
increased serum creatinine
estimated glomerular filtration rate
egfr
postmarketing reports
nephrotic syndrometenofovir df
increased creatinine-rare
renal failure
acute tubular necrosis
proximal renal tubulopathy
including
fanconi syndrome
nephrogenic diabetes insipidus-frequency
new onset
worsening
worsening renal impairment-postmarketing reports
renal insufficiency
interstitial nephritis
including
acute cases
tenofovir prodrugs
frequency
renal impairment
including
renal failure
fanconi syndrome
increased creatinine
grade
grade
grade
emtricitabine-tenofovir df
rilpivirine
trials in antiretroviral therapy-naive hiv
infected patients
median egfr ml/min at baseline
using emtricitabine
tenofovir alafenamide with elvitegravir
cobicistat
serum creatinine
mg/dl from baseline
week
median upcr
mg/g at baseline
week in a trial in virologically-suppressed tenofovir
df-treated patients
egfr ml/min at baseline
emtricitabine
tenofovir alafenamide with elvitegravir
cobicistat
serum creatinine
baseline
median upcr
mg/g at baseline
mg/g at week in a trial in renal dysfunction patients
baseline egfr
ml/min
using emtricitabine
tenofovir alafenamide with elvitegravir
cobicistat
serum creatinine
mg/dl at baseline
week
median upcr
mg/g at baseline
mg/g at week during phase trials
increase in serum creatinine
decrease in egfr
weeks of therapy with rilpivirine
changes
first weeks of therapy
mean change of mg/dl
range
mg/dl
creatinine
ml/min
m
range
m
egfr
weeks of therapy
subjects with mild
moderate baseline
renal dysfunction
serum creatinine increase
subjects with normal renal function
changes
subject discontinued therapy
increases in serum creatinine
proximal renal tubulopathy
tenofovir df
crcl
patients
stopping
drug
rhabdomyolysis
osteomalacia
bone abnormalities
contributing
fractures
hypokalemia
muscular weakness
myopathy
hypophosphatemia
result of proximal renal tubulopathy
renal failure
acute renal failure
fanconi syndrome
proximal renal tubulopathy
creatinine
nephrogenic diabetes insipidus
acute tubular necrosis
postmarketing experience with tenofovir df
emtricitabine/rilpivirine/tenofovir df
diarrhea
nauseaemtricitabine-tenofovir df
rilpivirine
nausea
pancreatic amylase-uncommon
increased lipaseemtricitabine
tenofovir alafenamide
nauseaemtricitabine
tenofovir df
diarrhea
abdominal pain
dyspepsia
vomiting-frequency
increased pancreatic amylase
serum amylase
lipaseemtricitabine
diarrhea
elevated amylase
including
elevated pancreatic amylase
elevated serum lipase
vomiting
abdominal pain
dyspepsiarilpivirine
nausea
pancreatic amylase-common
vomiting
diarrhea
abdominal discomfort
abdominal pain
lipase
dry mouthtenofovir df
diarrhea
vomiting
abdominal pain
abdominal distension
pancreatitis-postmarketing reports
increased amylase
clinical trials
nausea
common side effect
antiretroviral therapy-naive hiv
infected patients
using emtricitabine
tenofovir alafenamide with elvitegravir
cobicistat
diarrhea
nausea
therapy-naive patients
emtricitabine
tenofovir df
abdominal pain
dyspepsia
vomiting
therapy-naive patients
emtricitabine
tenofovir df
increased pancreatic amylase
times
upper limit of normal
uln
serum amylase
units/l
lipase
times uln
emtricitabine
tenofovir df
pancreatitis
abdominal pain
postmarketing experience with tenofovir df
emtricitabine/rilpivirine/tenofovir df
fatigue-postmarketing reports
weight increasedemtricitabine
tenofovir df
fatigue-common
fever
painemtricitabine
pain
astheniarilpivirine
fatigue-postmarketing reports
weight increasedtenofovir df
asthenia-frequency
vitamin d levelsantiretroviral therapy
frequency
increased weight
other side effects
fatigue
therapy-naive patients
emtricitabine
tenofovir df
fever
pain
therapy-naive patients
emtricitabine
tenofovir df
asthenia
postmarketing experience with tenofovir df
emtricitabine/rilpivirine/tenofovir df
postmarketing reports
severe skin
hypersensitivity reactions
including dress
emtricitabine
allergic reactionrilpivirine
postmarketing reports
severe skin
hypersensitivity reactions
including dress
tenofovir df
postmarketing reports
allergic reaction
including angioedema
emtricitabine
rilpivirine
tenofovir df
frequency
immune reconstitution/reactivation syndrome
autoimmune disorders in the setting of immune reconstitution
graves
disease
polymyositis
guillain-barre syndrome
emtricitabine
postmarketing reports
immune reconstitution syndromerilpivirine
immune reactivation syndrometenofovir df
postmarketing reports
immune reconstitution syndrome
emtricitabine
tenofovir alafenamide
decreased bone mineral density
bmd
fractures
excluding fingers
toes
frequency
increased biochemical markers of bone metabolism
bmdemtricitabine
tenofovir df
arthralgia
pain
myalgia-frequency
increased creatine kinaseemtricitabine
elevated creatine kinasetenofovir df
rhabdomyolysis
myopathy-frequency
decreased bmd
biochemical markers of bone metabolism
bone
abnormalities-postmarketing reports
osteomalacia
bone pain
fractures
combination
antiretroviral therapy
frequency
osteonecrosis
clinical trials
significant decline in bmd
therapy-naive hiv
infected patients
using emtricitabine
tenofovir alafenamide with elvitegravir
cobicistat
virologically-suppressed tenofovir
df-treated patients
emtricitabine
tenofovir alafenamide with elvitegravir
cobicistat
bmd
baseline
week
bmd
arthralgia
pain
myalgia
therapy-naive patients
emtricitabine
tenofovir df
increased creatine kinase
males
units/l
females
units/l
emtricitabine
tenofovir df
rhabdomyolysis
osteomalacia
muscular weakness
myopathy
proximal renal tubulopathy
rhabdomyolysis
muscular weakness
myopathy
postmarketing experience with tenofovir df
nasopharyngitis
pneumonia
sinusitis
upper respiratory tract infection
cough
rhinitis
therapy-naive patients
emtricitabine
tenofovir df
emtricitabine
tenofovir df
nasopharyngitis
pneumonia
sinusitis
upper respiratory tract infection
cough
rhinitistenofovir df
postmarketing reports
dyspnea
decreased neutrophils
mm
emtricitabine
tenofovir df
emtricitabine
tenofovir df
frequency
decreased neutrophilsemtricitabine
neutropenia-uncommon
anemiarilpivirine
decreased white blood cell count
hemoglobin
platelet count
increased glycosuria
hematuria
red blood cells/high power field
emtricitabine
tenofovir df
proteinuria
postmarketing experience with tenofovir df
emtricitabine
tenofovir df
frequency
increased glycosuria
hematuriatenofovir df
proteinuria-postmarketing reports
polyuria
rilpivirine
frequency
decreased basal cortisol
adrenocorticotropic hormone
acth
stimulated cortisol levels
adrenal insufficiency
abnormal mcg acth stimulation testtenofovir df
frequency
higher serum
parathyroid hormone levels
pooled phase trials
week
overall mean change from baseline in basal cortisol
nmol/l
mcg/dl
rilpivirine group
nmol/l
mcg/dl
efavirenz group
week
mean change from baseline in acth-stimulated cortisol levels
rilpivirine group
nmol/l
efavirenz group
nmol/l
mean values
acth-stimulated cortisol values at week
normal range
rilpivirine group
patients with normal mcg acth stimulation test at baseline
abnormal mcg acth stimulation test
peak cortisol level
mcg/dl
trial
patients in the efavirenz group
abnormal mcg acth stimulation test at week
rilpivirine patients
efavirenz patients
clinical significance of abnormal mcg acth stimulation tests
higher rate in the rilpivirine group
serious side effects
deaths
treatment discontinuations
adrenal insufficiency
side effects of odefsey
fda
healthcare professional for medical advice
discouragement
feeling
irritability
lack of appetite
loss of interest
pleasure
mental depression
thoughts
killing oneself
tiredness
trouble concentrating
trouble sleeping
body aches
pain
burning
crawling
itching
numbness
prickling
pins
needles
tingling feelings
chest pain
cough
difficulty with breathing
ear congestion
fever or chills
headache
loss of voice
stuffy nose
sneezing
sore throat
tightness in the chest
unsteadiness or awkwardness
unusual tiredness
weakness
weakness in the arms
hands
legs
feet
stomach discomfort
agitation
bloating
cloudy urine
bone pain
confusion
constipation
dark urine
decreased appetite
decreased urination
diarrhea
difficulty swallowing
dizziness
dry mouth
fast heartbeat
fast, shallow breathing
frequent urination
hostility
increased thirst
indigestion
irritability
hive-like swelling on the face
eyelids
lips
tongue
throat
hands
legs
feet
sex organs
lethargy
light-colored stools
muscle pain
cramps
muscle tenderness
wasting
weakness
nausea
pain in the stomach
side
abdomen
radiating
back
rapid weight gain
seizures
skin rash
hives
itching
sleepiness
swelling of the face
ankles
hands
feet
lower legs
vomiting
yellow eyes
skin
abnormal dreams
acid
sour stomach
back pain
belching
difficulty with moving
heartburn
pain in the joints
pain
tenderness around the eyes
cheekbones
stomach discomfort
upset
lack
loss of strength